These results suggest, for the first time, that deregulated CDK5/p35 signaling may have a pathogenic role in SSc fibrosis, and identify the TGF-ß-CDK5 axis as a potential novel target for therapy. This evidence concerns the gene CDK5 and systemic sclerosis.